Tangier disease: Epidemiology, pathophysiology, and management

American Journal of Cardiovascular Drugs

Volumn 12, Issue 5, 2012, Pages 303-311

  Puntoni, Mariarita ^a   Sbrana, Francesco ^b   Bigazzi, Federico ^b   Sampietro, Tiziana ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

coronary artery disease.; high density lipoprotein cholesterol; Tangier disease

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; FREE CHOLESTEROL; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB; UNCLASSIFIED DRUG;

ANEMIA; ARTERIAL WALL THICKENING; ARTICLE; CATABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL FEATURE; CORNEA OPACITY; CORONARY ARTERY DISEASE; FOAM CELL; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC POLYMORPHISM; HEART INFARCTION; HEPATOMEGALY; HETEROZYGOTE; HUMAN; HYPOALPHALIPOPROTEINEMIA; INTRON; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; QUALITY OF LIFE; RECTOSCOPY; RECTUM MUCOSA; RESTRICTION SITE; SPLENOMEGALY; STOMATOCYTOSIS; STROKE; TANGIER DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; ANIMALS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; CHILD; CHOLESTEROL; CHOLESTEROL ESTERS; DRUG DESIGN; HUMANS; LIPOPROTEINS, HDL; MUTATION; OXAZOLIDINONES; SULFHYDRYL COMPOUNDS; TANGIER DISEASE; TRIGLYCERIDES;

EID: 84866309579     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11634140-000000000-00000     Document Type: Article

References (59)

1. Fredrickson DS, Altrocchi PH, Avioli LV, et al. Tangier disease-combined clinical staff conference at the National Institute of Health. Ann Intern Med 1961; 55: 1016
2. Assman G, von Eckardstein A, Brewer HB. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver CS, Beaudet AL, Sly WS, editors. The metabolic and molecular bases of inherited disease. New York: Mc Graw- Hill, 2001; 2053-72
3. Sampietro T, Puntoni M, Bigazzi F, et al. Tangier disease in severely progressive coronary and peripheral artery disease. Circulation 2009; 119: 2741-2
4. Brunham LR, Singaraja RR, Hayden MR. Variation on a gene: Rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu Rev Nutr 2006; 26: 105-29
5. Oram JF, Vaugham AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006; 99: 1031-43
6. Oram JF, Heinecke JW. ATP-binding cassette transporter A1: A cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005; 85: 1343-72
7. Brousseau ME, Schaefer EJ, Dupuis J, et al. Novel mutations in the gene encoding ATP binding cassette 1 in four Tangier disease kindreds. J Lipid Res 2000; 41: 433-41
8. Clee SM, Kastelein JJP, van Dam M, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000; 106: 1263-70
9. The Human Gene Mutation Database [online]. Available from URL:http:// www.hgmd.cf.ac.uk/ac/gene.php?gene=ABCA1 [Accessed 2012 Jul 1]
10. Bocchi L, Pisciotta L, Fasano T, et al. Multiple abnormally spliced ABCA1 mRNAs caused by a novel splice site mutation of ABCA1 gene in a patient with Tangier disease. Clin Chim Acta 2010 Apr 2; 411 (7-8): 524-30
11. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, et al. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004; 114: 1343-53
12. Kyriakou T, Hodgkinson C, Pontefract DE, et al. Genotypic effect of the - 565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis. Arterioscler ThrombVasc Biol 2005; 25: 418-23
13. Tregouet DA, Ricard S, Nicaud V, et al. In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction. Arterioscler Thromb Vasc Biol 2004; 24: 775-81
14. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, et al. HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2010 Jan; 208 (1): 3-9
15. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.NEngl J Med 2011 Jan 13; 364 (2): 127-35
16. Rader DJ, Alexander ET, Weibel GL, et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009 Apr; 50 Suppl.: S189-94
17. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC transporter superfamily. J Lipid Res 2001 Jul; 42 (7): 1007-17
18. de La Llera-Moya M, Connelly MA, Drazul D, et al. Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J Lipid Res 2001 Dec; 42 (12): 1969-78
19. Schaefer EJ, Blum CB, Levy RI, et al. Metabolism of high density apolipoproteins in Tangier disease. N Engl J Med 1978; 299: 905-10
20. Assman G, Smootz E. High density lipoprotein infusion in plasma exchange in Tangier Disease. Eur J Clin Invest 1978 Jun; 8 (3): 131-5
21. Schaefer EJ, Anderson DW, Zech LA, et al. Metabolism of high density lipoprotein subfractions and costituents in Tangier disease following the infusion of high density lipoproteins. J Lipid Res 1981 Feb; 22 (2): 217-28
22. Navab M, Reddy ST, Van Lenten BJ, et al. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011 Apr; 8): 222-32
23. Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol 2003; 547 (Pt 1): 21-33
24. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-402
25. Park SH, Park JH, Kang JS, et al. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol 2003 Feb; 35 (2): 168-82
26. Watson A, Navab M, Hama S, et al. Effect of platelet activating factoracetylhydrolase on the formation and action of minimally oxided low density lipoprotein. J Clin Invest 1995; 95: 774-82
27. Watson A, Berliner J, Hama S, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-91
28. Navab M, Imes SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039-46
29. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate: changes that lead to fatty streak formation. Arteriosclerosis 1984; 4: 323-40
30. Berliner J, Navab M, Fogelman A, et al. Atherosclerosis: Dasic mechanism. Oxidation, inflammation and genetics. Circulation 1995; 91: 2488-96
31. Mineo C, Deguchi H, Griffin JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res 2006 Jun 9; 98 (11): 1352-64
32. Pisciotta L, Bocchi L, Candini C, et al. Severe HDL deficiency due to novel defects in the ABCA1 transporter. J Intern Med 2009 Mar; 265 (3): 359-72
33. Koseki M, Matsuyama A, Nakatani K, et al. Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 2009 Jun; 16 (3): 292-6
34. von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis 2006; 186: 231-9
35. Nofer JR, Remaleyc AT. Tangier disease: still more questions than answers CMLS. Cell Mol Life Sci 2005; 62: 2150-60
36. Hooper AJ, Robertson K, Ng L, et al. A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. Clin Chim Acta 2009 Nov; 409 (1-2): 136-9
37. Maekawa M, Kikuchi J, Kotani K, et al. Anovel missense mutation of ABCA1 in transmembrane alpha-helix in a Japanese patient with Tangier disease. Atherosclerosis 2009 Sep; 206 (1): 216-22
38. Zyss J, Be'hin A, Couvert P, et al. Clinical and electrophysiological characteristics of neuropathy associated with Tangier disease. J Neurol 2011 Dec 17: 1-5
39. von Eckardstein A, Huang Y, Kastelein JJP, et al. Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein depleted plasma of normolipidemic donors and apoA-I-deficient patients but not of Tangier Disease patients. Atherosclerosis 1998; 138: 25-34
40. Joyce C, Freeman L, Brewer Jr HB, et al. Study of ABCA1 function in transgenic mice. Arterioscler Thromb Vasc Biol 2003; 23: 965-71
41. Choi HY, Karten B, Chan T, et al. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type Cdisease. J Biol Chem 2003; 278: 32569-77
42. Hovingh GK, Van Wijland MJ, Brownlie A, et al. The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. J Lipid Res 2003; 44: 1251-5
43. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, et al. Circulation 2002; 106 (25): 3143-21
44. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: A potential new therapy for the prevention of atherosclerosis. Cardiol Rev 2010 May-Jun; 18 (3): 141-7
45. Miyazaki A, Sakuma S, Morikawa W, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterolfed rabbits. Arterioscler Thromb Vasc Biol 1995; 1882-8
46. Von Eckardstein A, Huang Y, Wu S, et al. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arteriosclerosis Thromb Vasc Biol 1995; 15: 1755-63
47. Eriksson M, Carlson L, Miettinen T, et al. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: Potential reverse cholesterol transport in humans. Circulation 1999; 100: 594-8
48. Bisoendial R, Hovingh G, Levels J, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-fensity lipoprotein. Circulation 2003; 107: 2944-8
49. Kyriakou T, Pontefract DE, Viturro E, et al. Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients. Hum Mol Genet 2007 Jun 15; 16 (12): 1412-22
50. Sorrenson B, Suetani RJ, Bickley VM, et al. An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations. Biochem Biophys Res Commun 2011; 409 (3): 400-5
51. Markel A. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. Isr Med Assoc J 2011 Jun; 13 (6): 368-74
52. Franceschini G, Werba JP, D'Aquarica AL, et al. Microsomal enzyme inducers raise plasma high density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia. Clin Pharmacol Ther 1995; 57: 434
53. Johns DG, Duffy J, Fisher T, et al. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors. Drugs 2012; 72 (4): 491-507
54. Sirtori CR. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention. Expert Opin Investig Drugs 2011; 20: 1543-54
55. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease.NEngl J Med 2010 Dec 16; 363 (25): 2406-15
56. Lüscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial. Eur Heart J 2012 Apr; 33 (7): 857-65
57. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal- PLAQUE): A randomised clinical trial. Lancet 2011 Oct 29; 378 (9802): 1547-59
58. F. Hoffmann-La Roche Ltd. Roche provides update on Phase III study of dalcetrapib. Media release dated 7th May 2012 [online]. Available from URL: http://www.roche.com/media/media-releases/med-cor-2012-05-07.htm [Accessed 2012 Jul 30]
59. Chenevard R, Hürlimann D, Spieker L, et al. Reconstituted HDL in acute coronary syndromes. Cardiovasc Ther 2012 Apr; 30 (2): e51-7